The invention provides new macrolides antibiotics of formula I with improved biological properties and having the formula
1
wherein R
1
, R
2
and R
3
are as herein described.
[EN] COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] COMPOSÉS EN TANT QUE MODULATEURS DE TRANSPORT NUCLÉAIRE ET LEURS UTILISATIONS
申请人:XW LAB INC
公开号:WO2019233447A1
公开(公告)日:2019-12-12
Provided are compounds of Formula I'-III', as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. Provided are also uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological disorders and diseases as well as certain types of cancer in humans.
The present invention discloses compounds of formulae (I) and (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR
申请人:Codd Ellen
公开号:US20080300236A1
公开(公告)日:2008-12-04
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.